Literature DB >> 35092463

Common mental disorders in South Asian patients with systemic sclerosis: a CIS-R-based cross-sectional study.

Debashish Danda1, Avanish Jha2, Abigail Ruth Gojer3, Ajit Kumar Surin4, Rachana Shenoy5, Sangeetha Priya2, Bijesh Yadav6.   

Abstract

There are not many studies looking at psychological impact of physical morbidities amongst patients with systemic sclerosis. Our aim was to describe the prevalence of common mental disorders (CMD) in systemic sclerosis patients, as against the population prevalence of CMDs. We also wanted to assess the utility of revised clinical interview schedule (CIS-R), a standardised interview technique for screening CMDs in systemic sclerosis (SSc). We prospectively recruited 93 consecutive patients fulfilling the 2013 ACR/EULAR criteria for systemic sclerosis from our single tertiary care centre. They were interviewed using CIS-R interviewing technique. These patients were assessed for the presence of psychiatric symptoms and presence of common mental disorders. Various associations of documented mental health issues and ICD-10-based psychiatric diagnosis were also analysed. A total of 29 (31%) out of 93 individuals with systemic sclerosis had a common mental disorder as per the earlier defined CIS-R cut off score of 12 and above. Fatigue (50.5%) and sleep issues (43%) were the commonest symptoms. Thirty-four patients (33.6%) fulfilled a total of 39 ICD-10 psychiatric diagnoses. Total CIS-R score is significantly associated with duration of Scleroderma in univariate analysis (p = 0.019), but there was no significant association on a multivariate analysis. Depression [18.3% as against 5% in Asian Indian general population], followed by obsessive compulsive disorder (OCD) [15.1% as against 0.7% in general population in India] were the top two ICD-10 psychiatric diagnosis in SSc. The occurrence of both depression and OCD, therefore, are far in excess compared to community prevalence. Additionally, modified CIS-R cut off of 10 instead of 12 can also improve the sensitivity (94%) of this screening interviewing tool for an ICD-10 psychiatric diagnosis. Depression is 3.4 times and OCD is 20 times commoner in our cohort of SSc than general population in India. A modified CIS-R cut-off score of 10 may further help in early recognition of these mental disorders in SSc and their referral to a psychiatrist.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Common mental disorders; Depression; Obsessive compulsive disorder; Scleroderma

Mesh:

Year:  2022        PMID: 35092463     DOI: 10.1007/s00296-022-05096-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  19 in total

1.  Cyclophosphamide versus placebo in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

2.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

3.  Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Authors:  Jean-Luc Vachiéry; Nazzareno Galiè; Joan Albert Barberá; Adaani E Frost; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Andrew J Peacock; Gérald Simonneau; Christiana Blair; Karen L Miller; Jonathan Langley; Lewis J Rubin
Journal:  J Heart Lung Transplant       Date:  2018-11-22       Impact factor: 10.247

Review 4.  Pathophysiology of systemic sclerosis: current understanding and new insights.

Authors:  Maurizio Cutolo; Stefano Soldano; Vanessa Smith
Journal:  Expert Rev Clin Immunol       Date:  2019-05-13       Impact factor: 4.473

5.  Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers.

Authors:  G Lewis; A J Pelosi; R Araya; G Dunn
Journal:  Psychol Med       Date:  1992-05       Impact factor: 7.723

Review 6.  Management of scleroderma renal crisis.

Authors:  Vivek Nagaraja
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

Review 7.  Systemic sclerosis.

Authors:  Christopher P Denton; Dinesh Khanna
Journal:  Lancet       Date:  2017-04-13       Impact factor: 79.321

Review 8.  Patients' Perspectives and Experiences Living with Systemic Sclerosis: A Systematic Review and Thematic Synthesis of Qualitative Studies.

Authors:  Ayano Nakayama; David J Tunnicliffe; Vivek Thakkar; Davinder Singh-Grewal; Sean O'Neill; Jonathan C Craig; Allison Tong
Journal:  J Rheumatol       Date:  2016-05-01       Impact factor: 4.666

Review 9.  Management of systemic sclerosis: the first five years.

Authors:  David Roofeh; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2020-05       Impact factor: 4.941

10.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.